DOSI Monitoring for Chemotherapy Response in Breast Cancer

(DOSI Trial)

This trial explores whether a new imaging method, Diffuse Optical Spectroscopy Imaging (DOSI), can predict breast cancer patients' responses to chemotherapy. DOSI uses harmless near-infrared light to assess tumor activity and can be performed easily at a doctor’s office. Women with breast cancer planning to undergo chemotherapy and surgery might be suitable candidates, particularly if their tumor is 2 cm or larger. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant advancements in breast cancer care.

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.

Research has shown that Diffuse Optical Spectroscopy Imaging (DOSI) is very safe for people. Early results suggest that DOSI, which uses harmless near-infrared light, causes no harm. This method involves low light exposure and requires no additional chemicals, making it gentle on the body. Studies, including one focused on using DOSI for breast cancer, reported no safety concerns, indicating that patients handle the imaging process well. DOSI is designed to be simple and safe, allowing for frequent scans without risk to patients.¹²³⁴⁵

Researchers are excited about Diffuse Optical Spectroscopy Imaging (DOSI) for breast cancer because it offers a non-invasive way to monitor how well chemotherapy is working. Unlike traditional imaging techniques, DOSI measures changes in tissue composition, such as blood and oxygen levels, providing real-time insights into tumor response. This means it could help doctors adjust treatments more quickly and effectively, potentially improving outcomes for patients undergoing chemotherapy.

Research has shown that Diffuse Optical Spectroscopy Imaging (DOSI) effectively tracks breast cancer tumors' responses to chemotherapy. In this trial, participants will be divided into two groups: one will undergo DOSI at a single time point, while the other will have DOSI at six different time points during neoadjuvant chemotherapy. Studies have found that DOSI provides clear images of a tumor's chemical makeup and monitors changes during treatment. This capability might help doctors determine early on if the chemotherapy is effective. DOSI uses safe, low-level light and doesn't require injections or radiation, making it easy and noninvasive. It has been successfully used to monitor tumor responses in women receiving chemotherapy before surgery.³⁶⁷⁸⁹